FDA public meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA will hold a public meeting Feb. 7 to discuss potential revisions of chemistry, manufacturing and controls supplement regulations, the agency announces Jan. 5. "FDA is evaluating how it could revise its regulations to allow for consideration of risk-based approaches based on manufacturing process understanding, including prior-knowledge of similar products, and overall quality systems to provide an enhanced risk-based approach to the regulatory process, which would reduce the number of supplements," FDA writes. The agency is "considering redefining what FDA considers to be a major manufacturing change, reducing the reporting burden for certain changes, and creating a new reporting category of manufacturing changes that would not require notification to FDA." The decision is in line with FDA's Pharmaceutical Current Good Manufacturing Practices for the 21st Century Initiative (1"The Tan Sheet" July 3, 2006, p. 6). Comments should be submitted March 7...
You may also be interested in...
Industry Input Will Bolster Risk-Based Inspection Approach – FDA’s Ellsworth
FDA is "hoping" to use future facility inspections to compile data that will strengthen the "process risk" prong of its risk-based site selection model by gaining knowledge about quality systems currently in use by industry, according to New Jersey District Director Douglas Ellsworth
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately-owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.